SNORA64 and prostate carcinoma: Furthermore, SNORA76 was found to be upregulated in gallbladder cancer compared to adjacent non-tumor tissues [39] and significantly downregulated in metastatic vs. non-metastatic prostate cancer xenograft models [43]; SNORD37 was found to be downregulated in non-small cell lung cancer [44] while SNORA64 was identified as significantly upregulated in pancreatic cancer patients [45] and acute myeloid leukemia patients [46].